论文部分内容阅读
目的观察拉米夫定配合阿德福韦酯初始抗病毒治疗对乙型肝炎肝硬化失代偿期患者血清指标的影响。方法选取2011年3月至2016年4月乙型肝炎肝硬化失代偿期患者110例,随机分为对照组及观察组,每组55例。对照组给予阿德福韦酯进行抗病毒治疗,同时给予水飞蓟宾胶囊;观察组在对照组基础上加用拉米夫定。观察并比较两组患者治疗后的血清各指标水平。结果观察组治疗后血清各指标水平改善均优于对照组,差异有统计学意义(P<0.05);观察组HBV-DNA转阴率为87.27%、HBe Ag转阴率为47.27%,均高于对照组的61.82%、25.45%,差异有统计学意义(P<0.05)。结论拉米夫定配合阿德福韦酯初始抗病毒治疗乙型肝炎肝硬化失代偿期临床疗效好,患者治疗后血清各指标改善明显。
Objective To observe the effect of lamivudine combined with adefovir dipivoxil on the serum indexes of hepatitis B patients with decompensated liver cirrhosis. Methods 110 patients with decompensated hepatitis B cirrhosis from March 2011 to April 2016 were randomly divided into control group and observation group with 55 cases in each group. The control group was given adefovir dipivoxil for antiviral therapy, while silybin capsules were given. The observation group was given lamivudine on the basis of the control group. Observed and compared the serum levels of the two groups of patients after treatment. Results The serum levels of each index in the observation group were better than those in the control group (P <0.05). The negative rate of HBV-DNA in the observation group was 87.27% and the negative rate of HBe Ag in the observation group was 47.27% 61.82% and 25.45% of the control group, the difference was statistically significant (P <0.05). Conclusion lamivudine combined with adefovir dipivoxil initial antiviral treatment of hepatitis B cirrhosis decompensation clinical efficacy, the patient after treatment to improve the significant indicators of serum.